Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Centogene N.V. (CNTG)

Centogene N.V. (CNTG)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 12,730
  • Shares Outstanding, K 27,080
  • Annual Sales, $ 50,020 K
  • Annual Income, $ -33,550 K
  • 60-Month Beta -0.81
  • Price/Sales 0.24
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade CNTG with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.67
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 05/21/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 1
  • High Estimate -0.27
  • Low Estimate -0.27
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4310 +9.05%
on 04/19/24
0.7500 -37.33%
on 04/02/24
-0.1800 (-27.69%)
since 03/22/24
3-Month
0.4310 +9.05%
on 04/19/24
1.2358 -61.97%
on 02/01/24
-0.7800 (-62.40%)
since 01/23/24
52-Week
0.4310 +9.05%
on 04/19/24
2.5200 -81.35%
on 04/25/23
-0.2622 (-35.81%)
since 04/21/23

Most Recent Stories

More News
Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing

Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly owned by the Public...

CNTG : 0.4900 (+4.23%)
Phreesia (PHR) Reports Q4 Loss, Tops Revenue Estimates

Phreesia (PHR) delivered earnings and revenue surprises of 7.69% and 2.56%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?

PHR : 23.54 (+5.04%)
CNTG : 0.4900 (+4.23%)
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Lags Revenue Estimates

ImmunoPrecise Antibodies Ltd. (IPA) delivered earnings and revenue surprises of -16.67% and 6.19%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the...

IPA : 1.2400 (-0.80%)
CNTG : 0.4900 (+4.23%)
Tabula Rasa Healthcare (TRHC) Reports Q4 Loss, Tops Revenue Estimates

Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -200% and 0.22%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

TRHC : 10.50 (+0.86%)
CNTG : 0.4900 (+4.23%)
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 22% and 16.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

SDGR : 25.14 (+2.65%)
CNTG : 0.4900 (+4.23%)
Is Intellia Therapeutics (NTLA) Stock Outpacing Its Medical Peers This Year?

Here is how Intellia Therapeutics, Inc. (NTLA) and Centogene N.V. (CNTG) have performed compared to their sector so far this year.

NTLA : 22.04 (+0.96%)
CNTG : 0.4900 (+4.23%)
Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Centogene N.V. (Nasdaq: CNTG),...

TWST : 31.42 (+6.69%)
CNTG : 0.4900 (+4.23%)
Phreesia (PHR) Reports Q3 Loss, Tops Revenue Estimates

Phreesia (PHR) delivered earnings and revenue surprises of 13.64% and 2.73%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?

PHR : 23.54 (+5.04%)
CNTG : 0.4900 (+4.23%)
Sema4 Holdings Corp. (SMFR) Reports Q3 Loss, Tops Revenue Estimates

Sema4 Holdings Corp. (SMFR) delivered earnings and revenue surprises of -5.26% and 8.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

SMFR : 0.3106 (+26.78%)
CNTG : 0.4900 (+4.23%)
Sangoma Technologies Corporation (SANG) Reports Q1 Loss, Lags Revenue Estimates

Sangoma Technologies Corporation (SANG) delivered earnings and revenue surprises of 62.50% and 2.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for...

SANG : 4.40 (-2.98%)
CNTG : 0.4900 (+4.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company's goal is to bring rationality to treatment decisions and to accelerate the development...

See More

Key Turning Points

3rd Resistance Point 0.6219
2nd Resistance Point 0.5858
1st Resistance Point 0.5280
Last Price 0.4900
1st Support Level 0.4341
2nd Support Level 0.3980
3rd Support Level 0.3402

See More

52-Week High 2.5200
Fibonacci 61.8% 1.7220
Fibonacci 50% 1.4755
Fibonacci 38.2% 1.2290
Last Price 0.4900
52-Week Low 0.4310

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar